SCHEMBL3972123

SCHEMBL3972123

CC1(C)CC=C(c2cc(C3(C(=O)O)CCCC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1

nearest known ligand 0.64

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3971620 0.93 — —
SCHEMBL14383690 0.92 CSF1R (0.47) CSF1R
SCHEMBL14383741 0.90 — —
SCHEMBL14383756 0.89 CSF1R (0.52) CSF1R
SCHEMBL14383726 0.89 — —
SCHEMBL14384458 0.89 CSF1R (0.53) CSF1R
SCHEMBL14383673 0.88 CSF1R (0.54) CSF1R
SCHEMBL14374981 0.88 CSF1R (0.52) CSF1R
SCHEMBL14375005 0.86 CSF1R (0.53) CSF1R
SCHEMBL14374877 0.86 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9403804-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-08-02 — — US disclosed
US-9403804-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-08-02 — — US disclosed
EP-2016058-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-01-06 — — EP disclosed
EP-2016058-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-01-06 — — EP disclosed
US-20140329815-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-11-06 — — US disclosed
US-20140329815-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-11-06 — — US disclosed
US-8815867-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2014-08-26 — — US disclosed
US-8815867-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2014-08-26 — — US disclosed
US-8815867-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2014-08-26 — — US disclosed
EP-2016058-A1 INHIBITORS OF C-FMS KINASE Janssen Pharmaceutica, N.V. (BE) 2009-01-21 — — EP disclosed
WO-2007124322-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 — — WO disclosed
WO-2007124322-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 — — WO disclosed
US-20070249608-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 — — US disclosed
US-20070249608-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 — — US disclosed
US-20070249608-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249608-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES CSF1R 59/4885
US-20140329815-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES CSF1R 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback